Comparison of the efficacy of lamivudine and enticavir in preventing hepatitis B virus reactivation in patients with B-cell non-Hodgkin lymphoma
10.3760/cma.j.issn.1008-6706.2019.21.020
- VernacularTitle: 恩替卡韦与拉米夫定预防B细胞非霍奇金淋巴瘤患者既往感染乙型肝炎病毒再激活的效果比较
- Author:
Lu FAN
1
;
Kun DING
2
;
Youde LIU
1
;
Xiangzhong LIU
3
;
Yan WANG
4
;
Dawei YU
5
Author Information
1. Department of Liver diseases 7th, Yantai Qishan Hospital, Yantai, Shandong 264001, China
2. Department of Internal Medicine, Yantai Qishan Hospital, Yantai, Shandong 264001, China
3. Liver diseases 8th Department, Yantai Qishan Hospital, Yantai, Shandong 264001, China
4. Department of Haematology, Yantai Yuhuangding Hospital, Yantai, Shandong 264001, China
5. Department of Cardiology, Yantai Yantaishan Hospital, Yantai, Shandong 264001, China
- Publication Type:Journal Article
- Keywords:
Lymphoma, non-Hodgkin;
Chemotherapy;
Hepatitis B virus;
Rituximab;
Entecavir;
Lamivudine;
Rituximab
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(21):2649-2654
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy of enticavir and lamivudine in preventing rituximab-associated hepatitis B virus(HBV) reactivation in patients with B-cell non-Hodgkin lymphoma complicated with resolved hepatitis B during chemotherapy.
Methods:This retrospective study included 216 B-cell non-Hodgkin lymphoma patients with complete data from January 2012 to January 2018 treated in 3 hospitals.Of 78 patients with resolved hepatitis B, they were divided into lamivudine prophylactic group(17 cases), entecavir prophylactic group(11 cases) and control group(50 cases). The changes of HBVM, HBV DNA and liver function before or after rituximab combination chemotherapy were analyzed.The incidence of HBV reactivation, liver function injury and chemotherapy delay were compared.
Results:Compared to the other 71 patients, 7 cases experienced HBV reactivation in 78 patients with resolved hepatitis B. There were no statistically significant differences between the two groups in patient demographics, pathological pattern, chemotherapy regimen.Six patients in the control group developed HBV reactivation(12%) and 1 patient in lamivudine prophylactic group(5.88%), none had HBV reactivation in enticavir prophylactic group.There was statistically significant difference among three groups(Fisher P=0.016). A total of 7 cases experienced HBV reactivation in 78 patients with resolved hepatitis B respectively, 2 cases in the first chemotherapy period, 2 cases in the third chemotherapy period, 1 case in the fifth chemotherapy period, the last one occurred after the completion of chemotherapy.Four patients had HBsAg reverse seroconversion, occurred in the 1, 3, 5 cycles during and after the completion of chemotherapy.Twenty patients (40.0%) experienced liver function parameters abnormal in the control group, 4 cases(23.5%) in lamivudine prophylaxis group, 2 cases (18.2%) in enticavir prophylaxis group during chemotherapy.
Conclusion:Antiviral prophylaxic therapy can potentially prevent rituximab associated HBV reactivation in patients with resolved hepatitis B. Entecavir can more reduce the risk of rituximab associated HBV reactivation than lamivudine.
